Ajinomoto Introduces AminoStable for Use in Pharmaceutical Applications and Cell Culture Market
Research has shown that Glutamine has many potential healthcare benefits; however use has been limited due to its lack of stability, especially in solution. The dipeptide, AminoStable, stabilizes the L-Glutamine in solution.
03/04/07 Ajinomoto Aminoscience LLC, the global leader in the amino acid marketplace announced the introduction of AminoStable, for use in pharmaceutical applications and for the cell culture market. AminoStable is L-Alanyl-L-Glutamine manufactured via a novel and efficient enzymatic method. This newly discovered method is a simple, cost effective process that produces peptides in high yield.
Research has shown that Glutamine has many potential healthcare benefits; however use has been limited due to its lack of stability, especially in solution. The dipeptide, AminoStable, stabilizes the L-Glutamine in solution. Other forms of L-Alanyl-L-Glutamine are available, however high costs have severely limited usage. Ajinomoto's new, efficient production processes addresses this issue. Ajinomoto expects the introduction of AminoStable will lead to increased use of L-Alanyl-L-Glutamine in pharmaceutical products, especially intravenous solutions and other application where increased use of L-Glutamine could result in improved patient care. The introduction of AminoStable is also expected lead to increased usage of L-Alanyl-L-Glutamine in cell culture media.
AminoStable will file for Drug Master File approval from the U.S. Food and Drug Administration (FDA). Once approved, pharmaceutical and biotech companies will be able to use AminoStable as an Active Pharmaceutical Ingredient in their medications and other medical specialty products.
Ajinomoto will produce AminoStable in its facility located in Raleigh, NC. This is the only US facility that produces pharmaceutical grade amino acids under cGMP conditions.
